CORVUS PHARMACEUTICALS

Corvus Pharmaceuticals to Present New CPI-818 Data at the International Conference on Malignant Lymphoma

17 May 2023 09:00:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results

08 May 2023 16:01:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report First Quarter 2023 Financial Results on May 8, 2023

20 Apr 2023 09:00:01 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid and Hematologic Cancers at the American Association for Cancer Research (AACR) Annual Meeting

17 Apr 2023 09:00:01 By Nasdaq GlobeNewswire

CPI-818 Data Highlights Potential for ITK Inhibition as a New Immunotherapy Approach for the Treatment of T Cell Lymphoma

03 Apr 2023 08:30:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results

28 Mar 2023 16:02:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023

21 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual Meeting

14 Mar 2023 16:35:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency Reversal

21 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

12 Dec 2022 10:00:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022

05 Dec 2022 08:30:00 By Nasdaq GlobeNewswire

James Rosenbaum Presented the Distinguished Service Award by the American College of Rheumatology

14 Nov 2022 08:30:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results

03 Nov 2022 16:05:02 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition

03 Nov 2022 09:52:48 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022

27 Oct 2022 16:05:01 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer

25 Oct 2022 16:05:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China

26 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference

06 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

08 Aug 2022 16:05:01 By Nasdaq GlobeNewswire

Corvus Pharmaceuticals to Provide Business Update and Report Second Quarter 2022 Financial Results on August 8, 2022

28 Jul 2022 16:05:01 By Nasdaq GlobeNewswire